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Abstract 
 The aim of this study was to evaluate the effects of dietary intervention on serum 
lipids, saturated fatty acids and trans-fatty acids in HIV-infected individuals on ART. This 
design was a non-randomized, non-controlled nutrition intervention study. The setting was in 
Referral Center in Infectious and Parasitic Diseases. Subjects: 57 HIV-infected patients, aged 
28.4–68.4 years, were recruited from the outpatient clinic of a reference center. Clinical and 
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biochemical data were collected from all before and after nutritional counseling. The majority 
of patients were male, with at least 8 years of schooling and 38.5% had BMI ≥ 25 kg/m2. 
Forty-eight (84%) patients had a family history of chronic diseases and the most common 
were coronary events (50%). All patients were exposed to antiretroviral therapy and 51% 
were using Protease Inhibitor. Twelve patients (21%) had a very low HDL-cholesterol and 26 
patients (45.5%) had hypertriglyceridemia. There were a significant increase in carbohydrate 
(p=0.02), protein (p=0.04), selenium (p<0.00005), and calcium (P=0.0007) intake and a 
significant decreased in total lipid (p=0.002), saturated fatty acids (p=0.0004), trans fatty 
acids (p=0.0005), and cholesterol total (p=0.0004) after dietary intervention. No significant 
difference was observed in energy, total fiber, polyunsaturated fatty acids and 
monounsaturated fatty acids after dietary intervention. This study suggested an efficacy of 
nutritional intervention in the prevention of changes in lipid profile of HIV-positive 
individuals on ART. These findings also suggest that nutritional intervention should be 
considered for all patients on ART.  
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Introduction 
 Since the advent of the antiretroviral therapy (ART) in the mid-1990s, it has been 
accompanied by an important decline in mortality and morbidity associated with Human 
Immunodeficiency Virus (HIV) infection (Hogg et al., 1997; Palella et al., 1998 and Mocroft 
et al., 1998). However, the benefits of ART are often accompanied by a substantial degree of 
long-term side effects that include dyslipidemia, insulin resistance, overt type 2 diabetes 
mellitus and changes in fat distribution, characterized by loss of peripheral deposits and/or 
accumulation of visceral adiposity (Carr, 2000; Guimarães et al., 2007 and Guimarães et al., 
2008). The pattern of these metabolic abnormalities in patients on TARV resembles that of 
the metabolic syndrome, which is known to increase the risk of cardiovascular disease. The 
cardiovascular impact of these metabolic abnormalities has been poorly evaluated and data on 
their association with antiretroviral drugs have been inconsistent and contradictory (Barbaro 
et al., 2003; Friis-Moller et al., 2007 and Worm et al., 2010). Preliminary studies indicate 
increased cardiovascular morbidity among HIV-infected individuals, suggesting that 
measures to reduce cardiovascular risk should be provided (Worm et al., 2010; Depairon et 
al., 2001; Torriani et al., 2008 and Guimarães et al., 2010), however, the implications of lipid 
disorders in this population are not yet fully known. 
European Scientific Journal    April 2013 edition vol.9, No.12    ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
34 
 
 Dyslipidemia has emerged as an important problem affecting HIV-infected patients 
on ART as well as hypertriglyceridemia. The HIV Medical Association of the Infectious 
Disease Society of America and the Adult AIDS Clinical Trials Group Cardiovascular 
Subcommittee drew up guidelines (Dube et al., 2003) for the evaluation and management of 
dyslipidemia based on a report published by the Adult Treatment Panel – ATP of the 
National Cholesterol Education Program – NCEP (NCEP III, 2001 and Grundy et al., 2004). 
These recommendations included target lipid levels and treatment of dyslipidemia in patients 
with HIV infection, in accordance with the estimated global cardiovascular risk calculated 
using the Framingham risk function, with particular attention to potential drug interactions 
with antiretroviral agents (ARV) and maintenance of virological control of HIV infection 
(Dube et al., 2003). All ATP reports have identified low-density lipoprotein cholesterol 
(LDL-c) as the primary target of cholesterol-lowering therapy and studies have shown that 
high serum concentrations of LDL-c are a major risk factor for coronary heart disease (CHD) 
(Shepherd et al., 2002 and Ford et al., 2002). 
 It is important to assume that dyslipidemia in HIV-infected patients, virologically 
well-controlled or not will have similar or even greater, long-term consequences than the 
general population will. Although unproven, the good results of lipid-lowering interventions 
will also be extending to HIV-infected individuals. 
 Despite the need of lipid-lowering drugs in some HIV-infected individuals, 
therapeutic lifestyle changes remain an essential modality in clinical management. In most 
instances, non pharmacological interventions should be first instituted and nutritional support 
should be considered in order to achieve the desired effects on lipid metabolism 
abnormalities. Therefore, the aim of this work was to evaluate the effects of dietary 
intervention on serum lipids, saturated fatty acids (SFA) and trans-fatty acids in HIV-infected 
individuals on ART. 
Patients and methods 
Design and subjects 
This was a non-randomized, non-controlled nutrition intervention study in which 
HIV-infected adult patients were recruited from the outpatient clinic of a reference center for 
infectious and parasitic diseases (Centro de Referência de Infecções Parasitárias Orestes 
Diniz of the Universidade Federal de Minas Gerais, Brazil), between October 2005 and 
December 2006. Inclusion criteria were: HIV-positive individuals as confirmed by 
polymerase chain reaction; age ≥ 18 years old; patients who have been receiving ARV drugs 
at the same dose for a minimum period of 3 months prior to admission. Exclusion criteria 
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were: metabolic disorders such as hyperlipidemia and diabetes mellitus; presence of 
lipodystrophy prior to the diagnosis of HIV infection; use of glucocorticoids or any other 
steroids, growth hormone, beta-blockers, thiazide or any drugs associated with metabolic 
abnormalities and body fat redistribution; any relevant clinical event at the time of enrollment 
to the study; pregnancy or breastfeeding; abnormal liver function tests; abnormal renal 
function; abnormal thyroid function; reported or proven history of alcohol or drug abuse; 
psychiatric conditions; patients who had interrupted the use of ARV drugs; patients who had 
attended only the first nutritional counseling session; refusal of the patient to participate.  
All selected patients received detailed information about all steps of the study and 
signed a written informed consent form. The study was approved by the ethics committee and 
has been performed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki. 
During the routine medical evaluation in the referral center 469 HIV-infected 
individuals were recruited, according to the order of arrival. Only 98 patients fulfilled the 
inclusion criteria and signed the informed consent form. Forty-one patients were excluded 
because they had attended only the first nutritional counseling session (Figure 1).  
HIV infected persons
(n = 469)
Persons that fulf illed
the inclusion criteria
(n = 98)
Included persons
(n = 57)
Excluded persons
Present only in f irst nutrition
counseling session
(n = 41)
Intervention on
lipid prof ile
 
Figure 1: Selection scheme of the HIV patients on  antiretroviral therapy (ART) that were submitted to 
nutritional counseling aiming an adequate lipid profile. 
 
Clinical evaluation 
All individuals included were evaluated following an ambulatory protocol. During the 
screening visit, blood tests were requested and the first appointment with a nutritionist was 
scheduled. Adherence to the study was secured through contact by telephone when it took the 
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confirmation of the date of appointment or reschedule. Data collected at first contact included 
age, gender, educational level, medical history, family history of chronic diseases, 
anthropometric measures and serum lipids levels from medical records. All participants 
completed a 24h recall. Information about the use of hypolipemiant and ARV drugs were also 
obtained from medical records. 
The first nutritional counseling session was then conducted with the objective of 
reducing dietary intake of total lipids, saturated fatty acids and trans-fatty acids. The group 
received counseling by the nutritionist such as food groups and specific items, frequency, and 
portion size of each food group to be consumed, and they were asked to follow a specific 
daily food plan. The food plan included daily consumption of whole grains and products, 3 
fruits, 2 portions of dark green vegetables, 2 portions of dark yellow vegetables and 2 units of 
Brazil nuts (10 grams). The participants were also instructed to reduce intake of red meat, 
replacing it by chicken or fish, to substitute margarine for halvarine or fruit jam or 
ricotta/yogurt pâté, to use olive oil for salad dressing, to use soy oil for cooking, to 
reduce/eliminate their intake of fried foods and sandwiched cookies, and increase the intake 
of low-fat milk. The same investigator gave all the information about the food plan. After the 
first nutritional counseling, another blood lipids tests were requested, to be carried out one 
week prior to the next visit.  
During this study, the participants had at least two sessions of nutrition counseling 
and the 24-hour recall was completed using a photograph album of food portions (Zabotto, 
1996) to help them to identify the size of portions. The quantity of food and/or preparations 
not illustrated in the photo album was estimated in accordance with the report given by the 
patient. The 24-hour recall was used to measure dietary intake, in both the beginning and at 
the end of the study, to verify the acceptability and compliance with the established 
methodology and to reinforce the key principles of the diet.  
Laboratory measurements and dyslipidemia classification 
Blood samples were taken after 12 h overnight fasting. The venous blood was 
collected with EDTA and plasma aliquots were obtained by ultracentrifugation. Total 
cholesterol (Tc) and triglycerides (Tg) were measured using the dry-chemical method in a 
Johnson chemical analyzer, model Vitros 750 or 950, with a Johnson ( kit, Rochester, NY, 
USA. High-density lipoprotein cholesterol (HDL-c) was measured by immunoinhibition 
assay using a Roche Benchtop Analyzer, model Cobas Mira, and a Labtest ( kit, Lagoa Santa, 
MG, Brazil.  Serum Low-density lipoprotein cholesterol (LDL-c) was calculated from 
quantitative measurements of total cholesterol and HDL-cholesterol and plasma triglycerides 
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- Friedewald formula (Friedewald, 1992). Subjects were considered dyslipidemic according 
to the following recommended cutoff points: Tc≥240 mg/dl (hypercholesterolemia), Tg 
between 200 to 499 mg/dl (hypertriglyceridemia), and Tg ≥500 mg/dl (very high 
hypertriglyceridemia) (NCEP III, 2001). 
Energy and nutrient intake 
The analysis of the 24-h recall was carried out with the use of DietWin diet analysis 
software (Reinstem, 1998). 
Anthropometric Measurements  
The anthropometric measurements were carried out by a single observer (the 
investigator). Data collected were weight (kg), height (cm), body circumferences (cm) and 
skinfold thickness (cm). Weight was measured using a mechanical platform scale (Welmy 
Indústria e Comércio de Balanças Ltda, São Paulo, SP, Brazil), with a maximum capacity of 
150 kg and increments of 100 grams. Height was measured using a wooden stadiometer fixed 
to the wall of the consulting room. The measurements of body circumference (abdomen, hip 
and arm) were obtained using a 0.7 cm wide, non-elastic measuring tape (defined as the 
smallest measurement between the lateral iliac crest and the lowest rib) and hip 
circumference (measured at the level of the widest circumference over the greater 
trochanters) (Leite et al., 2000). Skinfold thickness (tricipital, bicipital, suprailiac and 
subscapular) measurements were taken using an adipometer (Lange Skinfold Caliper, Beta 
Technology Inc., Santa Cruz, CA, USA). The skinfold thickness measurements were taken in 
triplicate, always on the right side of the body and fat percentage was calculated, using both 
the caliper method (Durnin & Womersley, 1974). 
Statistical analysis 
             The data entry was performed using the Epidata software program, version 3.1 
(Lauritsen; 2005). All the statistical analyses were carried out using the Stata software 
program, version 9.0 (Stata, 2006), and significance level was established at 95%. Normality 
was evaluated with the Shapiro-Wilk test and we used the Wilcoxon test for two matching 
variables and Student’s t-test for paired data were used to compare the biochemical, 
anthropometric and dietary data collected at the end of study with those collected at baseline 
for all subjects and for groups according to exposition to lipid-lowering drugs 
(Armitage,1995).  
Results 
Clinical and biochemical data were collected from 57 HIV-infected patients, aged 
28.4 to 68.4 years (44.9±9.4 years), before and after nutritional counseling. The majority of 
patients were male (65%), with at least 8 years of schooling (52.5%). The mean body mass 
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index (BMI) was 24.04 kg/m2 (16.2 to 35.2 kg/m2) and 38.5% had BMI ≥ 25 kg/m2. Forty-
eight (84%) patients had a family history of chronic diseases and the most common were 
coronary events (50%). All patients were exposed to antiretroviral therapy and 51% were 
using ART with Protease Inhibitor (PI). Twelve patients (21%) had a very low HDL-c and 26 
patients (45.5%) had hypertriglyceridemia (Table 1). 
Table 1 - Demographic, clinical, biochemical and treatment data of HIV-infected patients (n=57) 
Parameter n % 
Gender   
Male 37 65.0 
Female 20 35.0 
Education level (years of study)   
  0 4 7.0 
<8  30 52.5 
≥8  23 40.5 
BMI (kg/m2)   
<18.5 5 9.0 
18.5-24.99 30 52.5 
≥25 22 38.5 
Family history of chronic diseases   
No 9 16.0 
Yes 48 84.0 
Stroke (yes) 13 27.0 
Coronary event (yes) 24 50.0 
ART   
with IP 29 51.0 
without IP 28 49.0 
Serum lipids   
HDL-c very low 12 21.0 
Hypertriglyceridemia 26 45.5 
Very high hypertriglyceridemia 1 2.0 
Hypercholesterolemia 8 14.0 
Hypertriglyceridemia and hypercholesterolemia 4 7.0 
Very high hypertriglyceridemia and hypercholesterolemia 6 10.5 
BMI: body mass index / IP: Protease inhibitor / HDL-c: High-density lipoprotein cholesterol 
 
The median time of diagnosis of HIV infection was 6.74±3.32 years and three of them 
(5.0%) were aged ≥ 60 years. At the baseline and at the end of the study 14 (24.5%) and 12 
(21%) subjects had detectable viral load (p=0.82), respectively. Comparing the excluded 
individuals with those included, the family history and prevalence of diabetes (p=0.01) and 
arterial hypertension (p=0.009) were higher in the latter group.  
There was a significant increase in carbohydrate, protein, selenium, and calcium 
intake and a significant decrease in total lipid, saturated fatty acids (SFAs), trans fatty acids 
(trans FA), and cholesterol after dietary intervention (Table 2). No significant difference was 
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observed in energy, total fiber, polyunsaturated fatty acids (PUFAs) and monounsaturated 
fatty acids (MUFAs) after dietary intervention (Table 2). 
Table 2 - Nutrient intakes of HIV-infected patients at baseline and after dietary intervention (n = 57) 
Parameter 
Baseline End of study 
 
 
Mean±SD (Median) Mean±SD (Median) p 
Energy (Kcal) 2380.9±777.8 (2198.0) 2481.8±992.5 (2179.4) 0.83 
Carbohydrates (%) 50.1±9.4 (50.6) 54.1±5.8 (54.6) 0.02 
Proteins (%) 15.8±2.8 (15.4) 16.8±2.4 (16.6) 0.04 
Total Lipids (%) 33.7±8.6 (32.8) 29.1±5.3 (28.5) 0.002 
SFA(%) 9.9±4.4 (9.8) 7.5±2.8 (6.8) 0.0004 
Trans FA (g) 3.1±3.3 (2.0) 1.9±3.8 (0.0) 0.0005 
PUFA (%) 7.4±3.0 (7.1) 7.1±3.2 (6.8) 0.53 
MUFA (%) 10.1±4.1 (9.7) 10.2±5.1 (9.8) 0.46 
Total cholesterol (mg) 249.1±158.7 (217.7) 171.1±98.0 (180.3) 0.0004 
Total fiber (g) 41.2±16.5 (41.5) 45.6±19.7 (40.0) 0.20 
Selenium (µg) 33.1±136.2 (0.0) 44.3±83.7 (13) < 
 Calcium (mg) 683.9±571.9 (594.0) 986.5±486.6 (823.5) 0.0007 
SFA: saturated fatty acid/Trans FA: trans fatty acid/PUFA: polyunsaturated fatty acid 
MUFA: monounsaturated fatty acid 
 
Fridman and Wilcoxon tests 
There was statistically significant decrease in suprailiac skinfold, waist and hip 
circumferences, and in Tc, VLDL-c, LDL-c after dietary intervention (Table 3). 
Table 3 - Anthropometric and serum lipids data of HIV-infected patients at the baseline and at the end of the 
study (n= 57) 
Parameter Baseline End of the study  
Mean±SD (Median) Mean±SD (Median) p 
BMI (kg/m2) 24.0±3.8 (24.1) 24.0±3.4 (23.6) 0.09 
Circumferences (cm)    
Waist 87.3±10.9 (87.5) 86.3±10.0 (86.5) 0.02 
Hip 91.3±8.1 (90.0) 90.6±6.4 (89.5) 0.01 
Arm 33.2 ±3.8 (28.0) 28.4±3.2 (29.0) 0.18 
Skinfold thickness (mm)    
Triciptal   13.5±7.2 (12.0) 13.5±6.4 (12.0) 0.50 
Biciptal   7.3±3.8 (6.0) 7.3±3.8 (6.0) 0.84 
Suprailiac 20.8±13.8 (16.0) 20.1±12.8 (16.5) 0.005 
Subscapular   27.5 ±13.0 (25.0) 28.4±12.2 (27.0) 0.81 
Serum lipids (mg/dl)    
Tc 217.6±48.6 (218.0) 202.1±48.1 (201.0) 0.0007 
VLDL-c  45.3±6.7 (46.0) 40.2±17.1 (38.5) 0.03 
LDL-c 128.6±48.5 (131.0) 117.4±39.6 (112.0) 0.02 
HDL-c 40.5±10.4 (39.5) 42.0±11.7 (40.0) 0.32 
Tg 303.2±206.6 (238.0) 229.9±119.6 (210.0) 0.0001 
Tc: Total cholesterol/VLDL-c: Very low-density lipoprotein cholesterol/LDL-c: Low-density lipoprotein 
cholesterol/HDL-c: High-density lipoprotein cholesterol/Tg: Triglycerides 
 
Fridman and Wilcoxon tests 
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Discussion 
Metabolic disorders have been described in HIV-infected individuals on ART and 
have become an important clinical challenge in the global management of the disease (Dube 
et al., 2003). The nutritional aspects of HIV infection have changed over the last years and 
the weight gain, fat redistribution, obesity, and dyslipidemia, characterized by 
hypertriglyceridemia and/or hypercholesterolemia, are the new nutritional problems of those 
individuals (Shevitz, 2001). 
In these three months of non-randomized trial was suggested that nutritional 
intervention based on the NCEP ATP III guidelines (NCEP III, 2001) was able to prevent 
dyslipidemia induced by ART in HIV-infected patients. The nutritional counseling resulted in 
significant decreased in the serum levels of total lipids, namely, Tc, VLDL-c, LDL-c, Tg and 
significant increase in intake of calcium and selenium (Tables 2 and 3). These results are 
consistent with previous uncontrolled and controlled studies. Barrios et al., 2002 found a 
significant reduction in Tc and Tg in 230 HIV infected patients on antiretroviral therapy, who 
had good compliance to a low-fat diet for 6 months. The reduction in Tg levels was greater 
than in Tc levels. Batterham et al., 2003 showed in a retrospective study that there were 
significant reductions in Tc and Tg after changes in the diet. Recently, Lazzaretti et al., 2012 
demonstrated in a randomized clinical trial with 83 HIV-infected patients that dietary 
intervention prevents dyslipidemia associated with ART. The authors showed that in the 
group that received dietary intervention, the mean plasma levels of Tc, Tg, LDL-c, and BMI 
remained stable during the 12-month follow-up, while the control group presented the 
expected increment.  
HIV/AIDS has many faces as described by Mahlungulu et al. in 2009. There are 
major differences between HIV-positive individuals in developed and developing countries 
with regard to income level, availability of adequate nutrition, and access to basic healthcare 
or life-prolonging antiretroviral treatment. In addition, patient groups vary in terms of their 
response to the virus, stage of the disease, susceptibility to secondary infections, nutritional 
status, and individual response to the various treatments received. These complexities must 
be taken into account when formulating recommendations and guidelines on nutrient and 
energy for HIV-infected individuals. The nutritional guidelines used in this study focused on 
the quality of the lipids consumed, with the purpose of reducing the SFA and trans FA, and 
increasing MUFAs and PUFAs and fibers, as well as decreasing daily cholesterol intake. The 
decrease in intake of total lipids, SFA, trans FA, and cholesterol was the result of the 
recommendations for reducing the intake of red meat and replace it with chicken or fish, 
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substituting margarine for halvarine/fruit jam/ricotta or yogurt pate, use olive oil for salad 
dressing, using soybean oil for cooking, and reducing/eliminating their intake of fried foods 
and sandwich cookies, likewise, increasing the intake of low-fat dairy products (Table 2). 
These results are similar to those described by Lichtenstein et al., 1997, in which showed that 
the intake of foods with low level of trans FA and SFA was associated with decreased serum 
cholesterol. These findings are also corroborated by other studies (Mahlungulu et al., 2009; 
Fitch et al., 2006; Harnack, 2009).  
Adequate nutritional education promotes and maintains optimal immune function. 
Dietary support may, therefore, improve clinical outcomes in HIV-infected individuals by 
reducing the incidence of HIV-associated complications and attenuating the progression of 
HIV disease. Weight loss, muscle wasting and malnutrition are common in patients with HIV 
infection or AIDS (Vorster, 2004) and remain significant clinical problems (Grinspoon & 
Mulligan, 2003). Variation in the nutritional composition, as well as differences in the disease 
stage of the HIV-infected patients can significantly affect intake and absorption of food 
(Mahlungulu et al., 2009). There is evidence of severe protein deficiency in HIV/AIDS 
patients (Amadi et al., 2001; Kurpad et al., 2004) and protein deficiency is closely associated 
with energy deficiency. In the absence of adequate energy intake, body fat and protein are 
used as fuel sources. Fat is usually lost first and as body fat stores become progressively 
depleted, protein depletion becomes more striking. These changes are widely described in 
many wasting illnesses, but HIV seems to induce a special metabolic effect in the host 
involving a preferential loss of protein over fat (Macallan et al., 1995). Beside this, rates of 
protein turnover usually increase in HIV/AIDS (Macallan et al., 1995, 1998 e 2001; Harrison 
et al., 2002 and Yarasheski et al., 1998). 
Direct evidence for specific clinical benefit from known increments of protein intake 
is largely lacking and will depend on the nutritional and inflammatory state of the patient. 
The absence of carefully performed trials of nutritional supplementation makes it difficult to 
be absolutely certain as to how much nutrition intervention will improve the outcome of 
HIV/AIDS. However, it seems reasonable to assume that nutritional interventions in 
HIV/AIDS will enhance the defense of the organism against opportunistic infections, 
promote recovery and improve quality of life and survival despite the lack of properly 
conducted trials. 
In the meantime the overall evidence suggests that protein intake should be increased 
by 10% to match the increased intake of energy that is needed in HIV infected people 
(Hommes et al., 1991; Melchior et al., 1993; Grunfeld et al., 1992; Grinspoon et al., 1999). 
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This should be continued to maintain body nutrient stores during the chronic asymptomatic 
phase of HIV. When immunity fails and an opportunistic infection occurs, encouragement 
should be given to the patient to keep going with the extra 10%. It is unlikely that they will be 
able to eat any more than this if they are feeling unwell. Once the opportunistic clinical 
infection has cleared, additional amounts of energy and protein up to 30 to 50% over the 
customary intake should be encouraged to achieve nutritional recovery. Through this study 
was observed a significant increase of protein intake after nutritional intervention (Table 2). 
Although this recommendation is not yet a consensus and further controlled studies are 
needed, it would be important to maintain the balance between anabolism and catabolism of 
proteins. Scarcella et al. (2011) conducted a retrospective cohort study with 106 HIV/AIDS 
adult patients (84 in ART), all receiving food supplementation and peer-to-peer nutritional 
education. Nutritional status improvement was observed in both groups: with and without 
ART. However, the improvement in BMI was significant and substantially higher in ART 
patients because of the impact of ART on nutritional status of AIDS patients. The authors 
concluded that there was a synergic effect of integrating food supplementation, nutritional 
education and ART on the nutritional status of African AIDS patients. This finding highlights 
the importance of nutritional education in those patients.  
The patients also had an increase in calcium and selenium intake (Table 2). The 
observed increase in calcium intake was associated with the orientation of patients to enhance 
the intake of low-fat dairy products and dark green vegetables. The increase in selenium 
intake was correlated to the advice to consume two units Brazil-nut daily. This fact may have 
contributed to the observed changes in lipid profile of the patients, since it has been 
postulated that the antioxidant nutrient deficiency could be related to the development of 
hypercholesterolemia (Kang, Mehta and Bansal, 2000; Sabaté et al., 1993 and Kris-Etherton 
et al., 1999). 
According to the results, the decrease of serum Tg, Tc, VLDL-c and LDL-c was due 
to the nutritional intervention and not caused by reduced energy intake or by reducing the 
individuals’ weight (Table 2). Despite not having been observed change in body weight, there 
was a decrease in waist and hip circumferences and skinfold suprailiac, which suggest that 
changes in nutrients intake caused mobilization of adipose tissue in the central region of the 
body (Table 3).  
It is well known that HIV patients on ART may present body changes such as 
accumulation (lipohypertrophy) and/or with loss (lipoatrophy) of body fat (Sprinz et al., 
2010) and previous cohort study in the ART have consistently found an increase in body 
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weight after the diagnosis of HIV (Crum-Cianflone et al.,2010). The patients presented mean 
BMI within the limits of normality at baseline and at the end of the study (Table 3). After the 
dietary intervention some of the anthropometric changes associated with the lipodystrophic 
syndrome were probably prevented. Lipodystrophic syndrome is associated with accelerated 
lipolysis, which leads to futile cycling (Sekhar et al., 2002). In addition, lipodystrophy 
contributes to insulin resistance, diabetes mellitus and changes in fat distribution, 
characterized by loss of peripheral deposits and/or accumulation of visceral adiposity 
(Guimarães et al., 2007; Guimarães et al., 2008 and Crum-Cianflone et al.,2010). All these 
metabolic abnormalities can lead to increased risk of cardiovascular disease. Guimarães et 
al., 2007 demonstrated a strong correlation between intra-abdominal fat thickness and 
independent risk factors of cardiovascular disease: atherogenic lipid profile and insulin 
resistance. The increased waist circumference can be the expression of at least two fat 
components, visceral and subcutaneous ones. In particular, the visceral adipose tissue 
compartment, site of the local production of adipokines, is not an inert fat depot but a 
‘metabolically active’ one, with different impacts on cardiovascular risk factors and on 
atherosclerotic vascular damage (Carr & Cooper 2000; Nicklas et al. 2004; Kuk et al., 2006; 
Ronti, Lupattelli & Mannarino, 2006; Després et al., 2008 and Lupattelli et al., 2011). 
Studies performed before the advent of ART associated HIV infection with low HDL-c levels 
(Grunfeld et al., 1992). More advanced stages of HIV infection and lower CD4 lymphocyte 
count have been associated with lower HDL-c levels (Shor-Posner et al., 1993) and it has 
been shown that HDL-c levels may remain low despite ART (Riddler et al., 2003). However, 
Scarcella et al., 2011 showed significant increment in HDL-c with ART. The data found in 
this word did not show increase in serum levels of HDL-c. It could be because this 
lypoprotein frequently increases with the level of physical activity. The patients were mostly 
sedentary and remained so throughout the study, although they had been instructed to walk 
daily (Table 3). However, this study was not designed to evaluate the role of physical 
exercise on lipid profile. 
At present, there is no enough evidence that physical activity has considerable 
benefits for lipid control in HIV infected patients. Terry et al., 2006 concluded that 30 HIV 
infected patients with lipodystrophy and dyslipidemia submitted to a short-term intervention 
of low-lipid diet and aerobic exercise training (12 weeks) were able to increase their 
functional capacity without any consistent changes in plasma lipid levels. Fitch et al., 2006 
also failed to show improvement in lipid profile in a randomized study with 28 HIV-infected 
individuals with metabolic syndrome whose were submitted to an intensive lifestyle 
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modification program, which included a dietary intervention and physical activity. After 6 
months, despite improvement in anthropometric variables, blood pressure and physical 
activity, there were no consistent changes in lipid profile.  
Limitations 
Some limitations were noted and must be acknowledged in this study. Although it is a 
prospective study, the number of subjects was not high, thereby limiting the power and 
accuracy of the analysis. Indeed, this did not allow us to carry out the linear regression 
analysis in order to evaluate the effects of dietary components on serum lipids adjusting to 
the use of antiretroviral drugs, as well as the associations could not be said to be causal. Other 
limitation was the lack of HIV-negative controls. Despite limitations, these findings suggest a 
good effect of dietary intervention in preventing dyslipidemia in this setting.  
Conclusion 
ART is associated with potentially atherogenic adverse lipid profile in HIV infected 
patients and measures to reduce cardiovascular risk should be provided. Current guidelines 
recommend the diet as a first - step intervention for those individuals with ART-related 
dyslipidemia and nutritional support should be considered in order to achieve the desired 
effects on lipid metabolism abnormalities. By the results of this work was possible to suggest 
an efficacy of nutritional intervention in the prevention of changes in lipid profile of HIV-
positive individuals on ART. These findings also indicate that nutritional intervention should 
be considered for all patients on ART. However, we do believe that prospective randomized 
controlled studies are the key to test the effectiveness of dietary intervention in revert marked 
changes in lipid profile in HIV patients on ART and to evaluate the impact of this 
intervention on clinical outcomes associated with lipid profile. 
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